1-10 of 10
Karla V. Ballman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma

Scott M. Schuetze, Karla V. Ballman, Rachel Heise, Kristen N. Ganjoo, Elizabeth J. Davis, Suzanne George, Melissa A. Burgess, Edwin Choy, Dale R. Shepard, Gabriel Tinoco, Angela Hirbe, Ciara M. Kelly, Steven Attia, Hari A. Deshpande, Gary K. Schwartz, Brittany L. Siontis, Richard F. Riedel, Margaret von Mehren, Erin Kozlowski, Helen X. Chen, Caroline Astbury, Brian P. Rubin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4584–4592.
https://doi.org/10.1158/1078-0432.CCR-23-3817
Published: 15 October 2024
View article titled, A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
Open the PDF for A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma in another window
Includes: Supplementary data
Journal Articles

Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma

Adrian Marino-Enriquez, Jan Philipp Novotny, Doga C. Gulhan, Isabella Klooster, Antuan V. Tran, Macy Kasbo, Meijun Z. Lundberg, Wen-Bin Ou, Derrick L. Tao, Daniel F. Pilco-Janeta, Victor Y. Mao, Frank T. Zenke, Brittaney A. Leeper, Prafulla C. Gokhale, Glenn S. Cowley, Laurence H. Baker, Karla V. Ballman, David E. Root, Joachim Albers, Peter J. Park, Suzanne George, Jonathan A. Fletcher
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5128–5139.
https://doi.org/10.1158/1078-0432.CCR-23-0998
Published: 15 December 2023
View article titled, Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Open the PDF for Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)

Lee D. Cranmer, Yao Lu, Rachel S. Heise, Karla V. Ballman, Elizabeth T. Loggers, Seth M. Pollack, Michael J. Wagner, Denise K. Reinke, Patrick Schöffski, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1068–1076.
https://doi.org/10.1158/1078-0432.CCR-22-1564
Published: 14 March 2023
View article titled, Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <em>Post Hoc</em> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Open the PDF for Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <em>Post Hoc</em> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406) in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma

Laura M. Madanat-Harjuoja, Kelly Klega, Yao Lu, David S. Shulman, Aaron R. Thorner, Anwesha Nag, William D. Tap, Denise K. Reinke, Lisa Diller, Karla V. Ballman, Suzanne George, Brian D. Crompton
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2579–2586.
https://doi.org/10.1158/1078-0432.CCR-21-3951
Published: 13 June 2022
View article titled, Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Open the PDF for Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

Mark Jesus M. Magbanua, Oleksandr Savenkov, Erik J. Asmus, Karla V. Ballman, Janet H. Scott, John W. Park, Maura Dickler, Ann Partridge, Lisa A. Carey, Eric P. Winer, Hope S. Rugo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4911–4920.
https://doi.org/10.1158/1078-0432.CCR-20-1329
Published: 15 September 2020
View article titled, Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab
Open the PDF for Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab in another window
Includes: Supplementary data
Journal Articles

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, Giuseppe Galletti, Seaho Kim, Daniel Worroll, John Stewart, Atef Zaher, Ted P. Szatrowski, Karla V. Ballman, Katsuhiro Kita, Shinsuke Tasaki, Yang Bai, Luigi Portella, Brian J. Kirby, Fred Saad, Mario A. Eisenberger, David M. Nanus, Paraskevi Giannakakou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1880–1888.
https://doi.org/10.1158/1078-0432.CCR-18-0320
Published: 15 March 2019
View article titled, Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Open the PDF for Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

Himisha Beltran, Clara Oromendia, Daniel C. Danila, Bruce Montgomery, Christopher Hoimes, Russell Z. Szmulewitz, Ulka Vaishampayan, Andrew J. Armstrong, Mark Stein, Jacek Pinski, Juan M. Mosquera, Verena Sailer, Rohan Bareja, Alessandro Romanel, Naveen Gumpeni, Andrea Sboner, Etienne Dardenne, Loredana Puca, Davide Prandi, Mark A. Rubin, Howard I. Scher, David S. Rickman, Francesca Demichelis, David M. Nanus, Karla V. Ballman, Scott T. Tagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 43–51.
https://doi.org/10.1158/1078-0432.CCR-18-1912
Published: 03 January 2019
View article titled, A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Open the PDF for A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers in another window
Includes: Supplementary data
Journal Articles

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

Raymond Y. Huang, Rifaquat Rahman, Karla V. Ballman, Sara J. Felten, S. Keith Anderson, Benjamin M. Ellingson, Lakshmi Nayak, Eudocia Q. Lee, Lauren E. Abrey, Evanthia Galanis, David A. Reardon, Whitney B. Pope, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 575–581.
https://doi.org/10.1158/1078-0432.CCR-14-3040
Published: 31 January 2016
View article titled, The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
Open the PDF for The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab in another window
Journal Articles

Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

Jann N. Sarkaria, Brett L. Carlson, Mark A. Schroeder, Patrick Grogan, Paul D. Brown, Caterina Giannini, Karla V. Ballman, Gaspar J. Kitange, Abjahit Guha, Ajay Pandita, C. David James
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2264–2271.
https://doi.org/10.1158/1078-0432.CCR-05-2510
Published: 11 April 2006
View article titled, Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response
Open the PDF for Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response in another window
Journal Articles

PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.

Donkena Krishna Vanaja, Karla V Ballman, Bruce W Morlan, John C Cheville, Roxann M Neumann, Michael M Lieber, Donald J Tindall, Charles Y F Young
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (4): 1128–1136.
https://doi.org/10.1158/1078-0432.CCR-05-2072
Published: 17 February 2006
View article titled, PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Open the PDF for PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. in another window